Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
BioLineRx Ltd. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics primarily for oncology and rare disease indications. The company’s activities center on discovering, in-licensing, and advancing drug candidates through clinical development, with the goal of addressing unmet medical needs in cancer treatment and stem cell mobilization. BioLineRx is listed on NASDAQ and the Tel Aviv Stock Exchange, reflecting its dual U.S. and Israeli capital markets presence.
The company was founded in 2003 and has evolved from a broad early-stage drug discovery platform into a more focused late-stage clinical development organization. Its strategy shifted over time toward prioritizing assets with clearer regulatory and commercial pathways, particularly its lead clinical candidate motixafortide (BL‑8040), which has become the primary driver of corporate value and strategic focus.
Business Operations
BioLineRx operates primarily through a single operating segment focused on drug development, encompassing research, clinical trials, regulatory activities, and partnership management. The company does not currently generate significant recurring product revenue and instead relies on equity financing, milestone payments, and collaboration-related income to fund operations. Its pipeline development activities are conducted through internal management teams and external contract research organizations.
The company’s most advanced asset, motixafortide, is a CXCR4 antagonist designed to mobilize hematopoietic stem cells and enhance immune-oncology treatments. BioLineRx has entered into commercial and development partnerships related to this asset, allowing it to leverage external manufacturing, commercialization, and late-stage development capabilities while retaining an economic interest. Data inconclusive based on available public sources regarding the full scope of all active subsidiary entities, as BioLineRx primarily operates through the parent company structure.
Strategic Position & Investments
BioLineRx’s strategic direction emphasizes late-stage clinical development and potential commercialization of motixafortide while selectively advancing or out-licensing earlier-stage pipeline programs. Growth initiatives have focused on maximizing the value of its lead asset through regulatory approvals, geographic expansion via partners, and label expansion into additional oncology-related indications.
Historically, the company has expanded its pipeline through in-licensing transactions and internal R&D, rather than large-scale acquisitions. Its investment priorities remain concentrated on clinical trials, regulatory submissions, and post-approval commitments associated with motixafortide. BioLineRx maintains exposure to emerging oncology approaches, including immune modulation and stem cell mobilization, though its broader early-stage portfolio has been streamlined over time.
Geographic Footprint
BioLineRx is headquartered in Israel, with its principal executive offices located in Modi’in, Israel. The company maintains a significant operational and capital markets presence in the United States, largely driven by its NASDAQ listing, clinical trial activities, and investor base.
Its clinical development programs are conducted across multiple international regions, including North America, Europe, and Israel, depending on trial design and regulatory requirements. Commercial reach outside Israel is primarily achieved through strategic partners, giving BioLineRx international exposure without maintaining large-scale physical operations across all markets.
Leadership & Governance
BioLineRx was founded by Morris Laster, who played a central role in shaping its early discovery-driven model. Over time, leadership has transitioned toward executives with clinical development, regulatory, and capital markets experience, reflecting the company’s evolution into a late-stage biotech organization. The leadership philosophy emphasizes capital discipline, partnership leverage, and advancing assets with clear clinical differentiation.
Key executives include:
- Marina Konopleva, PhD – President and Chief Executive Officer
- Philip Serlin – Chief Financial Officer
- Dror Harats, MD – Chairman of the Board
- Noam Gershon – Chief Operating Officer
The board and management team collectively oversee strategy, risk management, and compliance, with governance practices aligned to requirements for companies listed on NASDAQ and subject to SEC filings.